The Cigna Group (NYSE:CI) Stake Boosted by Bellevue Group AG

Bellevue Group AG increased its stake in The Cigna Group (NYSE:CI - Free Report) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 125,205 shares of the health services provider's stock after acquiring an additional 6,798 shares during the period. Bellevue Group AG's holdings in The Cigna Group were worth $34,574,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Sterling Financial Group Inc. acquired a new position in shares of The Cigna Group during the 4th quarter valued at $4,367,000. Principal Financial Group Inc. lifted its stake in shares of The Cigna Group by 3.6% during the third quarter. Principal Financial Group Inc. now owns 323,911 shares of the health services provider's stock worth $112,216,000 after purchasing an additional 11,228 shares in the last quarter. Deroy & Devereaux Private Investment Counsel Inc. lifted its stake in shares of The Cigna Group by 1.1% during the fourth quarter. Deroy & Devereaux Private Investment Counsel Inc. now owns 75,837 shares of the health services provider's stock worth $20,942,000 after purchasing an additional 858 shares in the last quarter. Valley Wealth Managers Inc. grew its stake in shares of The Cigna Group by 2.8% in the fourth quarter. Valley Wealth Managers Inc. now owns 56,933 shares of the health services provider's stock valued at $15,721,000 after buying an additional 1,548 shares in the last quarter. Finally, KBC Group NV raised its holdings in shares of The Cigna Group by 1.5% during the 4th quarter. KBC Group NV now owns 550,638 shares of the health services provider's stock valued at $152,053,000 after buying an additional 8,077 shares during the period. Institutional investors and hedge funds own 86.99% of the company's stock.

The Cigna Group Stock Performance

Shares of CI traded up $1.00 during midday trading on Tuesday, hitting $334.01. 1,825,726 shares of the stock traded hands, compared to its average volume of 1,700,114. The firm has a market capitalization of $91.41 billion, a PE ratio of 27.29, a price-to-earnings-growth ratio of 0.98 and a beta of 0.47. The business's 50 day moving average price is $324.38 and its two-hundred day moving average price is $309.74. The Cigna Group has a 1-year low of $262.03 and a 1-year high of $370.83. The company has a debt-to-equity ratio of 0.70, a quick ratio of 0.72 and a current ratio of 0.66.

The Cigna Group (NYSE:CI - Get Free Report) last released its quarterly earnings results on Friday, May 2nd. The health services provider reported $6.74 earnings per share for the quarter, beating analysts' consensus estimates of $6.35 by $0.39. The Cigna Group had a return on equity of 18.61% and a net margin of 1.39%. The company had revenue of $65.45 billion for the quarter, compared to analysts' expectations of $60.39 billion. During the same quarter in the previous year, the company posted $6.47 earnings per share. The business's revenue for the quarter was up 14.4% compared to the same quarter last year. Equities research analysts predict that The Cigna Group will post 29.77 EPS for the current fiscal year.

The Cigna Group Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 18th. Stockholders of record on Tuesday, June 3rd will be paid a $1.51 dividend. The ex-dividend date is Tuesday, June 3rd. This represents a $6.04 annualized dividend and a dividend yield of 1.81%. The Cigna Group's payout ratio is 49.35%.

Analyst Upgrades and Downgrades

CI has been the topic of a number of analyst reports. Wells Fargo & Company dropped their price objective on shares of The Cigna Group from $370.00 to $341.00 and set an "equal weight" rating on the stock in a research note on Tuesday, February 4th. Sanford C. Bernstein downgraded The Cigna Group from an "outperform" rating to a "market perform" rating and set a $323.00 target price for the company. in a research note on Thursday, February 6th. UBS Group cut their price target on The Cigna Group from $410.00 to $390.00 and set a "buy" rating on the stock in a research note on Monday, February 3rd. Robert W. Baird lowered their price objective on The Cigna Group from $388.00 to $362.00 and set an "outperform" rating for the company in a research note on Tuesday, April 15th. Finally, Truist Financial upped their target price on The Cigna Group from $375.00 to $385.00 and gave the company a "buy" rating in a research report on Friday, April 11th. Two investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $378.22.

Insider Activity

In other The Cigna Group news, insider Nicole S. Jones sold 4,904 shares of the company's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $308.12, for a total value of $1,511,020.48. Following the completion of the sale, the insider now directly owns 29,421 shares in the company, valued at $9,065,198.52. This represents a 14.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Elder Granger sold 2,376 shares of The Cigna Group stock in a transaction on Friday, March 14th. The shares were sold at an average price of $310.35, for a total value of $737,391.60. Following the transaction, the director now owns 5,471 shares in the company, valued at approximately $1,697,924.85. This trade represents a 30.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 43,751 shares of company stock valued at $13,603,991. Company insiders own 0.70% of the company's stock.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.